Q3 EPS Estimate for DENTSPLY SIRONA Lowered by Analyst

Key Points

• Analysts at Leerink Partners have revised DENTSPLY SIRONA's Q3 2025 earnings per share estimate from $0.46 to $0.45, with a full-year consensus estimate of $1.84 per share.
• DENTSPLY SIRONA reported Q3 earnings of $0.52 per share, exceeding analyst expectations of $0.50, but revenue declined by 4.9% year-over-year.
• Investors will receive a quarterly dividend of $0.16 per share on October 10th, representing a yield of 4.9%.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a research note issued on Thursday, August 7th. Leerink Partnrs analyst M. Cherny now forecasts that the medical instruments supplier will post earnings of $0.45 per share for the quarter, down from their previous forecast of $0.46. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.84 per share. Leerink Partnrs also issued estimates for DENTSPLY SIRONA's Q4 2025 earnings at $0.48 EPS, FY2027 earnings at $2.34 EPS and FY2028 earnings at $2.64 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.02. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%. The firm had revenue of $936.00 million during the quarter, compared to analyst estimates of $929.67 million. During the same period in the previous year, the company earned $0.49 EPS. The company's revenue for the quarter was down 4.9% on a year-over-year basis.

A number of other analysts have also recently weighed in on XRAY. Piper Sandler lowered their price target on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Stifel Nicolaus lowered their price target on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a research report on Friday, August 8th. UBS Group lowered their price target on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Morgan Stanley cut DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price target on the stock. in a research report on Tuesday, April 15th. Finally, Wall Street Zen cut DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research report on Saturday. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $18.64.

DENTSPLY SIRONA Stock Performance

Shares of XRAY traded up $0.68 on Monday, reaching $13.73. 3,166,929 shares of the stock traded hands, compared to its average volume of 2,997,092. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -2.90, a P/E/G ratio of 0.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11. DENTSPLY SIRONA has a 12 month low of $12.16 and a 12 month high of $27.48. The stock's 50-day moving average price is $15.59 and its 200-day moving average price is $15.81.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds have recently added to or reduced their stakes in XRAY. Vanguard Group Inc. increased its holdings in DENTSPLY SIRONA by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after purchasing an additional 557,329 shares during the period. Price T Rowe Associates Inc. MD boosted its position in DENTSPLY SIRONA by 11.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after acquiring an additional 1,412,517 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in DENTSPLY SIRONA by 4.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock valued at $180,445,000 after acquiring an additional 538,531 shares in the last quarter. Lazard Asset Management LLC boosted its position in DENTSPLY SIRONA by 23.0% during the 4th quarter. Lazard Asset Management LLC now owns 8,044,228 shares of the medical instruments supplier's stock valued at $152,678,000 after acquiring an additional 1,505,928 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of DENTSPLY SIRONA by 21.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,851,869 shares of the medical instruments supplier's stock worth $130,045,000 after purchasing an additional 1,230,944 shares in the last quarter. Institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 10th. Shareholders of record on Friday, September 26th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 annualized dividend and a yield of 4.7%. DENTSPLY SIRONA's payout ratio is -13.50%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.